Jinjia Group: Restrictions Lifted on Controller, Investigation and Detention on Director

Regulations by 2FIRSTS, edited by Sophia
May.06.2024
Jinjia Group: Restrictions Lifted on Controller, Investigation and Detention on Director
Recent announcements from Jinjia Corporation (002191) reveal lifted restrictions on Qiao Luyu but investigation and detention of Li Dehua.

Recently, listed company Jinjia Group (002191) on the Shenzhen Stock Exchange has issued a series of announcements. Firstly, the disciplinary commission in Enyang District, Bazhong City has lifted the detention measures against Qiao Luyu. Secondly, the company's director and deputy general manager, Li Dehua, has been placed under investigation and detained.

 

According to relevant documents issued by the Supervision Committee of Enyang District, Bazhong City, the actual controller and chairman of the company, Qiao Luyu, is under investigation and has been placed under detention. On April 27, 2024, the company received a notice from the Supervision Committee of Enyang District, Bazhong City, lifting the detention of Qiao Luyu (Enjianjie Lutong [2024] No. 2), indicating that the Supervision Committee of Enyang District, Bazhong City has lifted the detention measures against Qiao Luyu. Currently, Qiao Luyu is able to carry out his duties as the chairman and legal representative of the company as normal, and the company's director and general manager, Hou Xudong, no longer acts on behalf of the company's chairman and legal representative.

 

Jinjia Group: Restrictions Lifted on Controller, Investigation and Detention on Director
Announcement | Image source: Jincare Group

 

On May 1st, the company received a notification from the Jinzhou District Supervisory Committee in Dalian City regarding the investigation and detention of the company's director and deputy general manager, Li Dehua.

 

Jinjia Group: Restrictions Lifted on Controller, Investigation and Detention on Director
Announcement | Image Source: Jincar Group

 

Jiangjia Group stated that the company has a sound governance structure and internal control mechanism, operating in compliance with laws, regulations, and rules such as the Company Law, the Shenzhen Stock Exchange Listing Rules, the Corporate Governance Guidelines for Listed Companies, and the company's articles of association. The company has already made proper arrangements for the work related to Li Dehua, and the ongoing investigation will not have a significant impact on the company's daily operations. All production and operational activities of the company are proceeding as usual.

 

Jinjia Corporation stated that as of the date of this announcement, the company is not aware of the progress and conclusion of the investigation. The company will continue to monitor the developments of the investigation and adhere to relevant laws and regulations, fulfill its disclosure obligations in a timely manner, and alert of any related risks.

 

According to the 2023 annual report of Jinjia Group, Li Dehua was born in 1968, is of Chinese nationality, does not have permanent residency abroad, has a high school education, and has been employed by Jinjia Group since 1996. He currently serves as a director, executive deputy general manager, and general manager of the production and marketing branch of the company, as well as holding other positions such as executive director of Shenzhen Qianhai Blueberry Culture Communication Co., Ltd. In 2023, Li Dehua received a total pre-tax compensation of 2.361 million yuan from the company.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
At the 2026 NACS Show in Las Vegas, Philip Morris International (PMI) showcased its ZYN nicotine pouches, IQOS heated tobacco products and U.S. investments. A 2Firsts review of FDA records found that several ZYN products displayed at the booth were not on the agency's marketing authorization list, including certain nicotine strengths and flavors. A PMI booth representative also confirmed that IQOS is currently sold in three U.S. states, while the newer IQOS ILUMA system remains under FDA review.
EXPO
Oct.10
2Firsts Data|China’s Vape-Related Exports Rose 3.3% in August 2026 as UK Shipments Jumped 51.4% and U.S. Exports Fell 12.4%
2Firsts Data|China’s Vape-Related Exports Rose 3.3% in August 2026 as UK Shipments Jumped 51.4% and U.S. Exports Fell 12.4%
China exported $979 million of vape-related products in August 2026, up 3.3% from a year earlier but down 6.4% from July. The UK replaced the U.S. as the main source of growth: UK-bound shipments jumped 51.4% to a 2026 high of $177 million, while exports to the U.S. fell 12.4% to $339 million. Shipments to markets outside the U.S. increased 14.2%, broadening growth beyond the market that had driven July’s rebound.
News
Sep.23 by 2Firsts Perspectives
Why AIRSCREAM Built its European Production Hub for Regulated Market Growth
Why AIRSCREAM Built its European Production Hub for Regulated Market Growth
AIRSCREAM’s production hub in the Czech Republic brings nicotine pouch manufacturing, e-liquid bottling, product documentation, warehousing and international logistics into one operation, giving brands and commercial partners a practical platform from which to launch, expand and enter new markets.
Market
Sep.16 by 2Firsts Perspectives
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23
PMI CEO Attends Opening of IQOS Global Flagship in Tokyo’s Ginza as 1,814 Limited ILUMA i PRIME Sets Launch
PMI CEO Attends Opening of IQOS Global Flagship in Tokyo’s Ginza as 1,814 Limited ILUMA i PRIME Sets Launch
IQOS opened its first global flagship, IQOS Flagship Ginza, in Tokyo on September 4, 2026, replacing the former IQOS Store Ginza after nearly a decade of operation. The new location expands conventional product retail into member lounges, digital experiences, art installations and brand programming. IQOS also launched a Ginza-exclusive IQOS ILUMA i PRIME set limited to 1,814 individually numbered units, priced at JPY11,980, or about US$77. PMI Sales Strategy Consultant Yuji M. later said on LinkedIn that more than 500 people had lined up from the night before the opening.
Sep.07
Australian Coalition Unveils Illicit Tobacco Plan With 80% Excise Cut and Legal, Taxed Vapes and Nicotine Pouches
Australian Coalition Unveils Illicit Tobacco Plan With 80% Excise Cut and Legal, Taxed Vapes and Nicotine Pouches
Australia’s Coalition has unveiled a national illicit-tobacco policy that would cut tobacco excise by 80% and create legal, regulated and taxed adult markets for vaping products and nicotine pouches if it wins government. The plan proposes an excise of A$0.50 per millilitre of e-liquid and A$0.025 per milligram of nicotine in pouches, alongside A$200 million in additional enforcement and a A$60 million three-year public-awareness campaign. The Coalition says the package would narrow the price advantage of illicit products and undermine organised crime, while Labor and public-health groups warn that dramatically cheaper cigarettes could reverse long-term declines in smoking.
Sep.03